Barclays’s BioNTech BNTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-22,500
Closed -$2.05M 5274
2025
Q1
$2.05M Hold
22,500
﹤0.01% 2608
2024
Q4
$2.56M Buy
+22,500
New +$2.57M ﹤0.01% 2701
2024
Q3
Sell
-45,000
Closed -$3.62M 5304
2024
Q2
$3.62M Buy
+45,000
New +$4.11M ﹤0.01% 1737
2024
Q1
Sell
-15,000
Closed -$1.58M 5092
2023
Q4
$1.58M Buy
+15,000
New +$1.51M ﹤0.01% 3099
2023
Q2
Sell
-15,000
Closed -$1.87M 4582
2023
Q1
$1.87M Sell
15,000
-38,400
-72% -$5.27M ﹤0.01% 2244
2022
Q4
$8.02M Buy
+53,400
New +$8.22M ﹤0.01% 1324

Other funds holding BNTX

Barclays's BNTX Position: Q1 2026 in Review

Barclays reduced its BioNTech (BNTX) stake by 12% in Q1 2026, selling an estimated $2.12M and leaving 152,473 shares worth $13.6M. The position accounts for ﹤0.01% of the portfolio, ranked #1286.

Barclays first reported a position in BNTX in Q1 2022 and has held it in 17 quarters since. The position peaked at $26.1M in Q1 2022. 272 funds tracked by Wall St. Rank hold BNTX as of Q1 2026.

  • Barclays held 152,473 shares of BioNTech worth $13.6M as of Q1 2026.
  • Barclays sold 20,616 BioNTech shares in Q1 2026, an estimated $2.12M.
  • BioNTech made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #1286 holding.
  • Barclays first reported a position in BioNTech in Q1 2022 and has held it in 17 quarters since.
  • Barclays's BioNTech position peaked at $26.1M in Q1 2022.
  • 272 funds tracked by Wall St. Rank held BioNTech as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.